Hearscape
← Therapeutics
Details checkedStrong evidenceCheckedcompany

ReSonance by Lineage Cell Therapeutics

Also known as: ReSonance, ANP1

Lineage Cell Therapeutics

Primary source
Company
Lineage Cell Therapeutics
Program Type
Therapeutic
Modality
Cell Therapy
Stage
Preclinical
Status
Active
Target Gene
—
Route / Mode
Implantable intracochlear cell transplant
Confidence
87%
Status Confidence
Status confirmed
Evidence Strength
Strong evidence
Last Reviewed
2026-05-31
Geography
United States, Denmark
Population
adult, auditory-neuropathy
Trial IDs
0
Mechanism

Allogeneic auditory neuron progenitor cell transplant is intended to repopulate the cochlea with functional auditory neurons in hearing loss.

Indications
Hearing LossSensorineural Hearing LossAuditory Neuropathy
Notes

Important auditory-neuron cell-therapy program; Demant-backed collaboration materially raised its strategic relevance in 2025.

Evidence & Sources
2 structured sources
company
Supports: canonicalName, aliases, company, mechanism, indications, stage, status
IDs: ReSonance, ANP1
Open
company
Supports: allCompanies, status, geography, notes
IDs: ReSonance, ANP1
Open
Key Events
2025-08-26
Lineage announced William Demant Invest collaboration to advance ReSonance ANP1
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2